White lung

MiNK Reports Fourth Quarter and Year-End 2023 Results

Retrieved on: 
Thursday, March 21, 2024
Pneumonia, Survival, Survival rate, NSCLC, Disease, Mink, Webcast, Patient, VV, Research, Gene, Cancer, Lung cancer, White lung, IND, Immunity, Society, Therapy, Paclitaxel, TCR, Cell, FDA, Nature Communications, Pharmaceutical industry

MiNK executives will host a conference call and webcast at 8:30 a.m.

Key Points: 
  • MiNK executives will host a conference call and webcast at 8:30 a.m.
  • “In 2023, MiNK made significant strides in advancing our allogeneic iNKT cell programs, contributing to a growing body of clinical data that underscores the unique advantages of iNKTs and their pivotal role in immunity,” said Dr. Jennifer Buell, Chief Executive Officer and President at MiNK.
  • The study reports survival rates exceeding 70% among patients on mechanical ventilation and surpassing 80% among those receiving VV ECMO support.
  • These results stand in stark contrast to the 10% survival rate observed in the in-hospital control during the same period.

RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs

Retrieved on: 
Tuesday, March 5, 2024
Infection, MCM, NIAID, NIH, ARS, TEL, FDA, SPHK2, Food, Acute radiation syndrome, RNCP, Bronchiolitis obliterans, Radiation, Mustard gas, HHS, Administration, COVID-19, Chem, ASPR, CCRP, Fibrosis, Acute respiratory distress syndrome, Development, White lung, Opaganib, Pharmaceutical industry

The overall evaluation will also include assessment of opaganib's efficacy against sub-chronic fibrosis and acute respiratory distress syndrome (ARDS) resulting from Sulfur Mustard exposure.

Key Points: 
  • The overall evaluation will also include assessment of opaganib's efficacy against sub-chronic fibrosis and acute respiratory distress syndrome (ARDS) resulting from Sulfur Mustard exposure.
  • "With the alarming increase in global geo-political instability, the opportunity to evaluate opaganib as a potential vital protective agent against chemical attack is inspiring.
  • "Opaganib is the first selective sphingosine kinase-2 (SPHK2) inhibitor investigational drug targeting sphingolipid metabolism to be evaluated as a chemical countermeasure.
  • Opaganib, a novel oral, small molecule pill with a five-year shelf-life, is easy to administer and distribute for use against potential chemical weapon attack, if approved by the FDA.

MGC Pharma Rebrands as Argent BioPharma in Strategic Transformation

Retrieved on: 
Tuesday, February 13, 2024
Alzheimer's disease, Argent, OTC, Growth, Drug development, MXC, GDP, Safety, ASX, Core values, Australian Securities Exchange, Health, Patient, Dementia, London Stock Exchange, IMP, Cerebral palsy, White lung, Neurology, Nanotechnology, Fine chemical

LONDON, Feb. 13, 2024 /PRNewswire/ -- MGC Pharmaceuticals Ltd (LSE: MXC), (OTC: MGCLF), (ASX: MXC)  Rebrands as Argent BioPharma in Strategic TransformationMarking a significant milestone in its evolutionary journey, MGC Pharma has officially announced its rebranding to Argent BioPharma, pending approval from its shareholders. This rebranding is the culmination of an extensive restructuring, incorporating significant American capital and operational revisions. Poised for growth, Argent BioPharma is now set to emerge as a key player in the biopharmaceutical industry, leveraging cutting-edge advancements in Polypharmacology and Nanotechnology. With its presence on both the London Stock Exchange and the Australian Stock Exchange, Argent BioPharma is well-positioned to make substantial contributions to enhancing medical treatment accessibility.

Key Points: 
  • LONDON, Feb. 13, 2024 /PRNewswire/ -- MGC Pharmaceuticals Ltd (LSE: MXC), (OTC: MGCLF), (ASX: MXC)  Rebrands as Argent BioPharma in Strategic Transformation
    Marking a significant milestone in its evolutionary journey, MGC Pharma has officially announced its rebranding to Argent BioPharma, pending approval from its shareholders.
  • Poised for growth, Argent BioPharma is now set to emerge as a key player in the biopharmaceutical industry, leveraging cutting-edge advancements in Polypharmacology and Nanotechnology.
  • With its presence on both the London Stock Exchange and the Australian Stock Exchange, Argent BioPharma is well-positioned to make substantial contributions to enhancing medical treatment accessibility.
  • As Argent BioPharma transitions from MGC Pharma, it stands ready to lead a new era in biopharmaceuticals, promising accessible and impactful healthcare solutions on a global scale.

MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications

Retrieved on: 
Tuesday, February 6, 2024
SARS-CoV-2, COVID-19, Mortality, Survival, Immunity, Pneumonia, VV, Nature Communications, Biomarker, Patient, Respiratory failure, Periodic breathing, Disease, Therapy, Doctor of Philosophy, University, Mink, Cancer, White lung, Survival rate, Viral pneumonia, Vaccine

These findings show that agenT-797 holds significant promise in improving patient survival and reducing secondary infections, all while maintaining a favorable safety profile.

Key Points: 
  • These findings show that agenT-797 holds significant promise in improving patient survival and reducing secondary infections, all while maintaining a favorable safety profile.
  • ARDS is a life-threatening, rapidly progressive form of respiratory failure, associated with approximately 40% mortality.
  • These data stand in stark contrast compared to 10% survival rate in the in-hospital control group at the same time.
  • The company plans to further advance agenT-797 in patients with viral ARDS through an externally funded, large platform trial.”
    The publication is available at: https://www.nature.com/articles/s41467-024-44905-z .

Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company

Retrieved on: 
Thursday, January 25, 2024
Heart, Windtree Therapeutics, Istaroxime, Therapy, Cardiogenic shock, White lung, Pharmaceutical industry

Windtree out-licensed global rights to AEROSURF® in 2022.

Key Points: 
  • Windtree out-licensed global rights to AEROSURF® in 2022.
  • “We appreciate the support of Deerfield in our efforts to strengthen our financial position with the completion of this transaction and the expected elimination the $15 million contingent liability.
  • As a result, we believe we have meaningfully strengthened and simplified our balance sheet,” said Craig Fraser, Windtree's President and Chief Executive Officer.
  • Along with significantly cutting our cash burn rate since the second half of 2022, I believe we have strengthened the company through recent transactions such as this one.

The Inner Circle Acknowledges, Josel Doyle as a Pinnacle Platinum Healthcare Professional for her contributions to Neonatology

Retrieved on: 
Monday, November 27, 2023
Winthrop University, Hospice and palliative medicine, Inner circle, NAS, JAAD, Transport, Pediatrics, Love, American Academy, Patient, Multimedia, Infection, Sleep-related breathing disorder, University of Kansas, Nuclear, Neonatal withdrawal, White lung, Stony Brook University Hospital, Hospital, Parent, Pediatrics (journal), Level 2, Education, Interior design, Nursing, Medicine, Neonatology

TOPEKA, Kan., Nov. 27, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Josel Doyle is acknowledged as a Pinnacle Platinum Healthcare Professional for her contributions to Neonatology.

Key Points: 
  • TOPEKA, Kan., Nov. 27, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Josel Doyle is acknowledged as a Pinnacle Platinum Healthcare Professional for her contributions to Neonatology.
  • Dr. Doyle pursued higher education at St. Georges University School of Medicine, earning undergraduate and medical degrees.
  • Recognized for her leadership early in her career, she also served as Chief Resident at Stony Brook University Hospital.
  • Dr. Doyle explained that neonatology is a subspecialty of pediatrics that consists of the medical care of newborn infants, especially ill and premature newborns.

Microbes, Mucus, and Brain Organoids--Experiments to Prevent and Treat Disease Launching on Next Space Station Resupply Mission

Retrieved on: 
Monday, October 30, 2023
Ageing, Commercial Resupply Services, United States Naval Research Laboratory, EDT, Organoid, Therapy, ISS National Lab, Scientific research on the International Space Station, Behavior, Biotechnology, EST, Ray (optics), SpaceX, White lung, Infection, Research, Mucus, SpaceX Dragon, Redwire, Dementia, University, Laboratory, Disease, Immune system, Risk, SPACE, University of California, San Diego, Brain, Medication, NASA, Alzheimer's disease, Patient, ISS, Boeing, NSF, International Space Station, Communications satellite, Pharmaceutical industry

Results may provide insights to mitigate the risk of infection on future space missions and space platforms.

Key Points: 
  • Results may provide insights to mitigate the risk of infection on future space missions and space platforms.
  • The U.S. National Science Foundation (NSF) continues its collaboration with the ISS National Lab by funding two biotechnology investigations on this mission.
  • An investigation from the University of California, San Diego, which builds on previous space station research, will explore microgravity's effects on stem-cell derived brain organoids.
  • This investigation aims to study accelerated aging in space to understand how cognitive decline happens in the human brain.

MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

Retrieved on: 
Thursday, September 28, 2023
ASPR, Code, ALI, Human services, United States Department of Health and Human Services, White lung, Development, MCM, Chlorine, Tokyo Stock Exchange, Biomedical Advanced Research and Development Authority, Acute respiratory distress syndrome, Standard Market Design, BARDA, Safety, Pharmaceutical industry

Two different nonclinical models were used to investigate the potential clinical utility of MN-166 (ibudilast) for the treatment of chlorine-induced lung damage.

Key Points: 
  • Two different nonclinical models were used to investigate the potential clinical utility of MN-166 (ibudilast) for the treatment of chlorine-induced lung damage.
  • The primary endpoint was the pulmonary function measure PaO2/FiO2, which is the ratio of arterial oxygen partial pressure to fractional inspired oxygen.
  • In the pilot design single-dose treatment regimen, the test subjects were treated only once after the Cl2 gas challenge was completed.
  • There is a great unmet medical need for treatments for chlorine gas exposure as there is no drug approved specifically for this indication.

Chrysalis Receives FDA Approval to Initiate Clinical Trials with Chrysalin™ (TP508)

Retrieved on: 
Tuesday, September 26, 2023
Research, FDA, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Science, Acute respiratory distress syndrome, Tissue, Pupa, US Foods, Radiation, Biomedical Advanced Research and Development Authority, Bone fracture, University, Office of Inspector General, U.S. Department of Health and Human Services, Human services, Safety, National Institute of Allergy and Infectious Diseases, Infection, Brain, COVID, Inflammation, Lung, Pulmonary fibrosis, UTMB, Fibrosis, Development, Ischemia, Patient, Diagnosis, Chronic radiation syndrome, Carney, NIAID, Trauma, UTHealth School of Dentistry, BARDA, IND, Food, White lung, Pharmaceutical industry

Chrysalis BioTherapeutics, Inc. announced today that the US Food and Drug Administration (FDA) has given the company permission to initiate human clinical trials aimed at treating acute lung failure.

Key Points: 
  • Chrysalis BioTherapeutics, Inc. announced today that the US Food and Drug Administration (FDA) has given the company permission to initiate human clinical trials aimed at treating acute lung failure.
  • Other animal studies show potential TP508 benefit in treating acute lung injury, chronic smoke inhalation, and mitigating radiation effects on brain and other tissues.
  • “TP508 is a natural regenerative peptide that accelerates tissue repair and revascularization while modulating the inflammatory response.
  • Chrysalis is using UTMB, Houston-area, and national advisors to advance TP508 for treating pulmonary indications.

ReAlta Life Sciences Announces Poster Presentation at the European Respiratory Society 2023 International Congress

Retrieved on: 
Tuesday, September 5, 2023
Research, Infectious Diseases, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, European Respiratory Society, Human, Protocol, Reactive airway disease, Toxicology, Hypoxia (medical), Medical research, Immune system, Fraunhofer Society, Rare, International Congress on Tuberculosis, POM, White lung, Pharmaceutical industry

ReAlta Life Sciences (“ReAlta”), Inc., a clinical-stage biotech company addressing life-threatening rare diseases through harnessing the power of the immune system, today announced that it will be presenting additional clinical data from its Phase 1b trial in healthy volunteers on RLS-0071 at the European Respiratory Society 2023 International Congress taking place in Milan, Italy on 9-13 September, 2023.

Key Points: 
  • ReAlta Life Sciences (“ReAlta”), Inc., a clinical-stage biotech company addressing life-threatening rare diseases through harnessing the power of the immune system, today announced that it will be presenting additional clinical data from its Phase 1b trial in healthy volunteers on RLS-0071 at the European Respiratory Society 2023 International Congress taking place in Milan, Italy on 9-13 September, 2023.
  • RLS-0071, the Company’s complement inhibitor and innate anti-inflammatory product candidate, is being developed as a treatment for hypoxic ischemic encephalopathy and other acute inflammatory and rare diseases.
  • The new data will be presented by Prof. Dr. Jens M. Hohlfeld, Division Director of Airway Research at the Fraunhofer Institute for Toxicology and Experimental Medicine (Hannover, Germany) and lead investigator on the Phase 1b trial.
  • Session 68 (PA608) – From bench to bedside: translational studies in airway diseases